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Abstract
The obligate intracellular pathogen Chlamydia trachomatis replicates within a membrane-bound inclusion that acquires
host sphingomyelin (SM), a process that is essential for replication as well as inclusion biogenesis. Previous studies
demonstrate that SM is acquired by a Brefeldin A (BFA)-sensitive vesicular trafficking pathway, although paradoxically, this
pathway is dispensable for bacterial replication. This finding suggests that other lipid transport mechanisms are involved in
the acquisition of host SM. In this work, we interrogated the role of specific components of BFA-sensitive and BFA-
insensitive lipid trafficking pathways to define their contribution in SM acquisition during infection. We found that C.
trachomatis hijacks components of both vesicular and non-vesicular lipid trafficking pathways for SM acquisition but that
the SM obtained from these separate pathways is being utilized by the pathogen in different ways. We show that C.
trachomatis selectively co-opts only one of the three known BFA targets, GBF1, a regulator of Arf1-dependent vesicular
trafficking within the early secretory pathway for vesicle-mediated SM acquisition. The Arf1/GBF1-dependent pathway of SM
acquisition is essential for inclusion membrane growth and stability but is not required for bacterial replication. In contrast,
we show that C. trachomatis co-opts CERT, a lipid transfer protein that is a key component in non-vesicular ER to trans-Golgi
trafficking of ceramide (the precursor for SM), for C. trachomatis replication. We demonstrate that C. trachomatis recruits
CERT, its ER binding partner, VAP-A, and SM synthases, SMS1 and SMS2, to the inclusion and propose that these proteins
establish an on-site SM biosynthetic factory at or near the inclusion. We hypothesize that SM acquired by CERT-dependent
transport of ceramide and subsequent conversion to SM is necessary for C. trachomatis replication whereas SM acquired by
the GBF1-dependent pathway is essential for inclusion growth and stability. Our results reveal a novel mechanism by which
an intracellular pathogen redirects SM biosynthesis to its replicative niche.
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Introduction
Chlamydia species are obligate intracellular pathogens that cause
a wide range of diseases in humans, including sexually transmitted,
ocular, and respiratory tract infections [1]. The capacity of
Chlamydia infections to lead to infertility and blindness, their
association with chronic diseases such as atherosclerosis, and the
extraordinary prevalence and array of these infections make them
public concerns of primary importance [1,2].
All Chlamydia species share a dimorphic developmental cycle
that allows them to survive within the hostile environment of the
host cell (reviewed in [3]). Chlamydia alternate between an
extracellular, spore-like infectious form termed the elementary
body (EB), and an intracellular, metabolically active but non-
infectious form termed the reticulate body (RB). Infection is
initiated by binding of the EB to the host cell where it is taken up
by an actin and Rho family GTPase-dependent process and
sequestered within a unique membrane bound compartment
called the inclusion [4]. Subsequently, the EB differentiates into an
RB and replicates by binary fission within the inclusion.
Concomitantly, the bacteria begin remodeling the inclusion
membrane by insertion of bacterial proteins that promote
segregation of the inclusion from the classical endosomal/
lysosomal transport pathway, that facilitate interactions of the
inclusion with the exocytic transport pathway, and that promote
migration of the inclusion along microtubules to the peri-Golgi
region [5,6]. The developing inclusion expands to accommodate
increasing numbers of bacteria and is stabilized by recruitment of
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intermediate filaments [7]. After 24–72 hours (hrs) of replication,
RBs redifferentiate back to EBs and are released from the host cells
by cell lysis or active extrusion [8].
Chlamydiae are one of the few known bacterial pathogens that
require host-derived membrane lipids, including sphingomyelin
(SM) and cholesterol, for intracellular growth and development
[6,9,10,11,12,13,14]. Recent work suggests that SM biosynthesis is
also required for homotypic fusion of multiple inclusions within the
same cell as well as for inclusion membrane stability [15].
Chlamydia are thought to acquire SM by vesicular trafficking via
multiple routes, including (1) the interception of SM-containing
Golgi-derived exocytic vesicles destined for the plasma membrane
(PM) [16,17,18], (2) fusion with multivesicular body (MVB)-
derived vesicles [15,19,20], and/or (3) Golgi fragmentation
[21,22]. SM acquisition by the inclusion is observed as early as
2 hrs post infection (hpi), with incorporation of SM into the
inclusion membrane and into the bacterial cell wall [6,10,
12,13,15,19,20,23]. Golgi fragmentation induced by C. trachomatis
has been shown to play an important role in SM acquisition
during the later stages of infection and may be required for
subsequent fusion with exocytic vesicles by a mechanism that
involves Rab6 and Rab11 [21,22]. SM transport to the inclusion is
partially abrogated by Brefeldin A (BFA), an inhibitor of vesicular
transport [6,24,25] and is accompanied by a decrease in inclusion
size [6], indicating that SM transport to the inclusion via vesicular
trafficking is important for inclusion growth. Importantly, BFA
treatment has no effect on bacterial replication [6], suggesting that
SM acquisition by a BFA-sensitive pathway is not essential for
replication and that C. trachomatis may acquire SM by additional
routes that involve BFA-insensitive and/or non-vesicular traffick-
ing pathways.
ADP ribosylation factors (Arfs) are small GTPases that are key
players in the regulation of vesicular transport where they function
to recruit coat proteins necessary for vesicle formation (reviewed in
[26]). Arf1 is localized in all three Golgi compartments, cis-, medial-
, and trans-Golgi, and cycles between an active GTP bound form
and an inactive GDP-bound form [27]. Arf1 activation is spatially
and temporally regulated by specific guanine nucleotide exchange
factors (GEFs), GBF1 (Golgi-specific BFA resistance guanine
nucleotide exchange factor 1) and BIG1/BIG2 (BFA-inhibited
guanine nucleotide exchange proteins 1 and 2) which are present
in the cis- and trans-Golgi, respectively [26,28,29,30,31,32,33].
BFA inhibits the activation of Arf1 by targeting GBF1 and BIGs
[29,34,35,36]. GBF1 is required for the assembly and mainte-
nance of the Golgi stack whereas BIGs are required for
maintenance of the trans-Golgi network [33,37]. Besides regulating
coat protein recruitment, Arf1 controls the actin cytoskeleton by
modulating the lipid microenvironment via recruitment of various
phosphoinositide kinases [38], and it also regulates the vimentin
architecture in cells [39]. Although Arf1 localizes to the inclusion
and has recently been implicated in Chlamydia infection [40,41],
the specific roles of Arf1 and its cis- and trans-Golgi-specific GEFS
in inclusion biogenesis and/or acquisition of SM has not been
previously investigated.
Until recently, vesicular trafficking of ceramide from the ER to
the trans-Golgi was believed to be essential for SM biosynthesis;
however, it is now appreciated that the major pathway of de novo
SM biosynthesis involves a cytosolic lipid transfer protein, called
CERT, that transports ceramide (the precursor for SM) from the
ER directly to the trans-Golgi, where it is converted to SM by one
of two SM synthases, SMS1 or SMS2 [42,43,44,45,46]. CERT
has three functional domains, an N-terminal PH (pleckstrin
homology) domain that binds phosphoinositide-4-phosphate
(PI4P) at the trans-Golgi, a FFAT (two phenylalanines in an acidic
tract) motif that binds integral membrane proteins, VAP-A and
VAP-B, at the ER, and a C-terminal START (steroidogenic acute
regulatory protein-related lipid transfer) domain that binds to and
extracts ceramide from the ER membrane [47]. CERT is
subjected to regulation within a serine repeat (SR) domain where
phosphorylation by Protein Kinase D and hyperphosphorylation
by Casein Kinase Ic2 (CKIc2) inactivates CERT while dephos-
phorylation by Protein Phosphatase 2Ce activates CERT
[48,49,50]. Transfer of ceramide from the ER to the Golgi via
CERT is thought to occur at ER-Golgi membrane contact sites
(MCS), sub-regions of the ER located very close to trans-Golgi
stacks [51,52]. The role of non-vesicular lipid transport pathways
during Chlamydia infection has not been previously explored.
In this study, we examined the role of specific host proteins
required for vesicular and non-vesicular lipid transport during
infection to define their contribution to SM acquisition, bacterial
replication, and inclusion biogenesis. We found that C. trachomatis
selectively co-opts GBF1 within the cis-Golgi compartment for
vesicle-mediated SM acquisition and that this source of SM
contributes to inclusion membrane growth and stability but that
GBF1 function is not required for bacterial replication. Unex-
pectedly, we discovered that C. trachomatis coordinates recruitment
of CERT and SM synthases to the inclusion and that subversion of
this lipid synthesis pathway is required for bacterial replication and
for efficient SM acquisition by C. trachomatis. We propose that C.
trachomatis utilizes separate lipid trafficking pathways to acquire SM
for distinct roles during infection: SM acquired by the GBF1-
dependent pathway is essential for inclusion growth and stability
while CERT-dependent transport of ceramide and subsequent
conversion to SM is necessary for C. trachomatis replication.
Results
GBF1 but not BIG1/2 function is partially required for SM
acquisition but dispensable for C. trachomatis replication
In an RNA interference (RNAi) screen for host factors required
for C. trachomatis L2 infection of Drosophila S2 cells, homologs of
Arf1 and its associated GEFs, GBF1 (localized to the cis-Golgi) and
BIG1 (localized to the trans-Golgi) were identified [53]. Since
Chlamydia is thought to occupy a post Golgi compartment and
Author Summary
C. trachomatis is the leading cause of non-congenital
blindness in developing countries and is the number one
cause of sexually transmitted disease and non-congenital
infertility in Western countries. The capacity of Chlamydia
infections to lead to infertility and blindness, their
association with chronic diseases, and the extraordinary
prevalence and array of these infections make them public
concerns of primary importance. This pathogen must
establish a protective membrane-bound niche and acquire
essential lipids from the host cell during infection in order
to survive and replicate. This study identifies novel
mechanisms by which C. trachomatis hijacks various lipid
trafficking proteins for distinct roles during intracellular
development. Disruption of these lipid trafficking path-
ways results in alterations in the growth and stability of its
protective niche as well as a defect in replication.
Understanding the molecular mechanisms of these host-
pathogen interactions will lead to rational approaches for
the development of novel therapeutics, diagnostics, and
preventative strategies.
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replication [6,21,22], we tested the hypothesis that spatially-
localized Arf1 function within the Golgi might be important for
SM acquisition and/or for C. trachomatis intracellular growth.
We first examined the localization of Arf1-GFP, GBF1, and
BIG1 during C. trachomatis infection of HeLa cells. We found that
GBF1 and BIG1 were localized to the fragmented Golgi around
the inclusion in C. trachomatis-infected cells and appeared to
maintain their cis and trans polarity, as observed in uninfected cells
(Figure 1A). GBF1 (Figure 1B) and BIG1 (data not shown) were
primarily localized adjacent to but not on the inclusion membrane.
Similar results were obtained in cells expressing GFP-tagged GBF1
(data not shown). In contrast, Arf1-GFP was found not only on
Golgi vesicles adjacent to the inclusion but was also localized to the
inclusion membrane, where it formed a thin rim of circumferential
staining (Figure 1B), consistent with previously published results
[40,41]. We noted a striking concentration of Arf1-GFP at the
region of two closely apposed inclusion membranes (Figure 1B).
To evaluate whether GBF1 or BIG1/2 activity was required for
Arf1-GFP recruitment to the inclusion membrane, we treated cells
with BFA, which inhibits both GBF1 and BIGs, and examined the
localization Arf1-GFP and GBF1. Exposure of the cells to BFA
resulted in dispersion of GBF1 and Arf1-GFP throughout the cell
and loss of the circumferential rim staining on the inclusion;
however, BFA had no effect on Arf1-GFP localization at abutting
inclusion membranes (Figure 1B). This finding suggests that GBF1
and/or BIG1/2 activities are required for Arf1 recruitment to the
outer region of the inclusion but that they are not necessary for
Arf1 maintenance at closely apposed inclusions.
To determine the specific contribution of the cis- versus trans-
Golgi compartments to SM acquisition, HeLa cells were depleted of
GBF1 or BIG1/2 by siRNA, infected with C. trachomatis, and then
examined by live-cell microscopy for SM acquisition as described in
the Materials and Methods. Protein depletion was assessed by
western blot analysis (Figure 1C). As shown in Figure 1D, labeled
lipids were readily visible inside bacterial inclusions in control
siRNA-treated cells and in cells depleted of BIG1 and/or BIG2. In
contrast, depletion of GBF1 resulted in ,60% reduction in SM
acquisition by the inclusion (Figures 1D and S1A; p,0.001). SM
acquisition was similarly reduced in cells treated with Golgicide A
(GCA), a GBF1-specific inhibitor [37] and with BFA ([17] and
Figures 1EandS1B). AsGCAtargetsGBF1selectively and does not
inhibit BIGS, these results suggest that the relevant target of BFA
during C. trachomatis L2 infection is GBF1.
We next tested whether GBF1 or BIG1/2 were required for
intracellular growth. GBF1 depletion (Figure S1B) or inhibition
with GCA or BFA (Figure S2) resulted in inclusions that were
smaller than those observed in control siRNA- or untreated cells.
Quantitation of inclusion size, as described in Materials and
Methods, revealed that the average inclusion size in GBF1-
depleted cells was decreased by 40% (p,0.001) compared to
control siRNA-treated cells (Figure S1D). In contrast, depletion of
BIG1 and/or BIG2 gave rise to inclusions that were slightly larger
than those observed in control siRNA depleted cells (Figures S1C
and S1D). Despite the changes in inclusion size, depletion of any of
the Arf1 GEFS did not decrease production of progeny; in fact, a
small increase in progeny was observed (Figure 1F). The reason for
the increase in progeny is not currently known.
Together, these results demonstrate that GBF1, but not BIG1/2
function, is required for vesicle-mediated SM acquisition and
inclusion growth but is dispensable for bacterial replication. These
findings indicate that the impact of disrupting GBF1 function on SM
acquisition is not an indirect result of altering Arf1-dependent
trafficking in the trans-Golgi, since depletion of BIG1 and/or BIG2
did not reduce SM acquisition or inclusion growth. We note that in
Drosophila S2 cells, depletion of either GBF1 or the single BIG1 was
sufficient to decrease inclusion formation [53]; this finding may
reflect differences in Golgi organization between Drosophila S2 and
mammalian cells, and/or it may reflect the fact that these proteins
mayhaveadditionalrolesbeyond thesecretorypathwayinhostcells.
GBF1 function is required for inclusion membrane
stability
We observed that interference with GBF1 function resulted in a
defect in SM acquisition by the inclusion, and recent studies have
shown that the inclusion membrane integrity is compromised
when host SM biosynthesis is inhibited [15]. Therefore, we tested
whether GBF1 plays a role in maintaining the integrity of the
inclusion membrane. Depletion of GBF1 (Figure 2A) or exposure
to GCA or BFA (Figure S2A) resulted in a loss of inclusion
membrane integrity, as evidenced by discontinuities in 14-3-3b
staining (which binds to the inclusion membrane protein, IncG)
and release of bacteria into the host cytoplasm at the broken
membrane sites. Quantitative analysis (as described in Materials
and Methods) revealed that ,80% of infected cells in which GBF1
function was inhibited exhibited broken inclusions (Figures 2 and
S2A). The loss of inclusion membrane integrity was observed at
mid- to late times of infection (data not shown), after significant
replication has occurred.
Recent studies have shown that the inclusion is stabilized by a
cage-like structure composed of F-actin and vimentin [7].
Although it has been reported that inhibition of SM biosynthesis
did not result in alteration of the vimentin or actin structure
around the inclusion [15], experiments using BFA have revealed
that perturbations in vesicular trafficking lead to reciprocal
changes in the architecture of the vimentin network in the host
cell, indicating a tight link between membrane trafficking and the
cytoskeleton [39]. Furthermore, Arf1 has been shown to regulate
actin dynamics at Golgi membranes [54]. We therefore considered
whether the loss of inclusion integrity observed upon disruption of
GBF1 function was due solely to the decrease in SM acquisition or
whether disruption of GBF1 function also affected the vimentin
and actin cage surrounding the inclusion. We examined the
localization of these cytoskeletal proteins in infected cells treated
with GBF1 siRNA or GCA. Disruption of GBF1 function caused
both the vimentin and actin cages to collapse to a thin,
hemispheric cup-like structure on the nuclear side of the inclusion
(Figures 2B, S2B, and S2C). In cells treated with either BFA or
GCA, we also observed less GBF1 staining surrounding the
inclusion, and GBF1 displayed a more compact Golgi-like
localization (Figure S2A). GBF1 inhibited cells were more sensitive
to Triton extraction (data not shown), similar to what has been
reported following disruption of the actin and vimentin cage
during infection [7], suggesting that the cytoskeletal cage is
compromised upon GBF1 inhibition.
Together, these results indicate that GBF1 function contributes to
the stabilityof the inclusionmembranebyamechanismthatinvolves
SM acquisition and/or maintenance of the vimentin and F-actin
cage around the inclusion; however, GBF1 function is not required
for intracellular replication. Given that SM biosynthesis is essential
for replication [6,12], our findings suggest that other lipid transport
mechanisms may be involved in the acquisition of host SM.
The ceramide transport protein, CERT and its ER binding
protein, VAP-A, are recruited to the inclusion
Since ceramide transport from the ER to the trans-Golgi by the
cytosolic lipid transporter, CERT, is the predominant pathway for
Role of Lipid Trafficking Pathways in Chlamydia Development
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dependent trafficking was involved in SM acquisition by C.
trachomatis. We first examined the localization of CERT during C.
trachomatis infection of HeLa cells that were transiently transfected
with CERT-GFP. In uninfected cells, CERT-GFP preferentially
localized to the Golgi as well as to punctate, vesicle-like structures
outside the Golgi (Figure S4 and [45,55]), which are thought to be
ER-derived (K. Kumagai and K. Hanada, personal communica-
tion). In C. trachomatis-infected cells, CERT-GFP was recruited to
the inclusion, exhibiting a non-homogeneous, patchy distribution
on the inclusion membrane surface (Figure 3A, B, D, E, Video S1).
CERT-GFP appeared on the same plane as but distinct from
localization of the C. trachomatis inclusion membrane protein, IncA
(Figure 3B). This pattern of CERT recruitment to the inclusion
was confirmed using an antibody to endogenous CERT (Figure
S3), demonstrating that localization was not an artifact of ectopic
expression. CERT-GFP also localized to C. trachomatis serovar D
inclusions (Figure 3B), suggesting that the recruitment to the
inclusion was not serovar-specific. CERT-GFP was recruited to
inclusions as early as 2 hpi, where nascent inclusions were
enveloped by CERT-GFP-containing vesicles that partially
overlapped with p58, a marker of the ER-Golgi intermediate
compartment (ERGIC) (Figure S4A).
CERT binding to VAP at the ER is required for CERT to
extract ceramide from the ER and deliver it to the trans-Golgi [45],
where ceramide serves as a substrate for SM synthesis by trans-
Golgi localized SMS1 and SMS2 [46,56]. Previous work suggests
that there is an intimate association of the ER with the chlamydial
inclusion [57,58]. We examined the localization of CERT and
VAP-A by co-expressing CERT-GFP and HcRed-VAP-A [45] in
infected cells and found that HcRed-VAP-A colocalized with
CERT-GFP at the inclusion at 2, 8, and 24 hpi (Figures 3C–E).
These results suggest that CERT may function to bring the ER
membrane in close apposition to the inclusion or that VAP-A is
recruited directly to the inclusion.
CERT is required for bacterial replication and SM
acquisition
Given the proximity of the Golgi and the striking recruitment of
CERT to the inclusion, we used three complementary approaches
to determine whether CERT plays a role in C. trachomatis infection:
(1) pharmacological inhibition of CERT by HPA-12, a synthetic
analog of ceramide that specifically inhibits CERT-mediated
ceramide transfer [59,60], (2) overexpression of Casein Kinase Ic2
(CKIc2), which plays a crucial role in down-regulating CERT
activity [48], and (3) depletion of CERT by siRNA.
We first examined inclusion morphology and progeny produc-
tion in cells treated with increasing concentrations of HPA-12.
Cells were infected for 1 hr and then incubated in the absence or
presence of HPA-12 for an additional 23 hrs. We observed a dose-
dependent decrease in inclusion formation (Figures 4A) and
progeny production (Figure 4B) in cells exposed to HPA-12,
resulting in a 96% reduction in progeny at 10 mM HPA-12
compared to DMSO (p,0.001). At the doses employed, HPA-12
did not affect host or bacterial cell viability nor did it affect
bacterial binding and entry (data not shown).
CKIc2 regulates CERT by hyperphosphorylation of a SR motif
located within the middle region, which induces an autoinhibitory
interaction between the PH and START domains. This event
interferes both with the ability of CERT to bind PI4P and with its
ability to transport ceramide, though CERT is still able to interact
with VAP-A at the ER [48,61]. Overexpression of CKIc2i s
sufficient to inhibit CERT function and to cause dissociation of
CERT from the Golgi complex [61]. In cells co-transfected with
CERT-GFP and HA-tagged CKIc2, we observed a significant
defect in inclusion development, with the appearance of small
inclusions (Figure 4C), similar to the results observed with HPA-12
(Figures 4A and 6C). Importantly, CERT-GFP was still recruited
to the inclusion in cells expressing HA-tagged CKIc2 (Figure 4C).
These results are consistent with the notion that CERT activity is
required for inclusion development and suggest that PI4P binding
is not required for CERT recruitment to the inclusion.
We next examined inclusion morphology in HeLa cells depleted
of CERT for 72 hrs and subsequently infected with C. trachomatis
for 24 hrs. The efficiency of CERT depletion was determined in
uninfected cells by western blot analysis (Figure 4D). Loss of
CERT activity was confirmed by demonstrating decreased
accumulation of BODIPY FL-SM and BODIPY FL-Ceramide
at the Golgi apparatus (Figure 4E). CERT depletion resulted in a
,66% (p,0.001) reduction in inclusion size as well as a ,60%
(p,0.001) decrease in progeny production (Figures 4F–G).
Depletion or inhibition of CERT sometimes resulted in the
appearance of inclusions containing aberrant appearing RBs
(Figure 4F and data not shown). Progeny formation was decreased
more robustly in HPA-12 treated cells than in CERT-depleted
cells, most likely because CERT depletion was not complete,
although we cannot rule out the possibility that HPA-12 may have
additional off-target effects.
We next explored whether CERT was required for the SM
accumulation in the inclusion by monitoring incorporation of
BODIPY FL-Ceramide. Since depletion of CERT led to a
significant reduction in inclusion size (Figure 4F), we monitored
lipid transport in the presence of the CERT inhibitor, HPA-12.
HeLa cells were infected for 20 hrs to allow inclusions to develop
to a large enough size for robust visualization by phase
microscopy, then exposed to HPA-12 for 3 hrs, and subsequently
pulse-labeled with BODIPY FL-Ceramide. The fluorescent lipid
Figure 1. GBF1 function is required for SM acquisition but not for C. trachomatis replication. (A) HeLa cells were infected with C.
trachomatis L2 for 24 hrs and then fixed and stained with antibodies to GBF1 (red) and BIG1 (green). Bacteria and host DNA were detected using DAPI
(blue). The cis and trans polarity of the Golgi was maintained in C. trachomatis L2-infected cells. N, host nucleus. *, inclusion. Scale bar=5 mm. (B) HeLa
cells were transfected with Arf1-GFP for 18 hrs, infected with C. trachomatis L2 for 24 hrs in the absence or presence of 10 mM BFA, and then fixed
and stained with antibodies to GBF1 (red). Enlargements of boxed regions are shown to the right. Images represent a single z slice from confocal
images. The exposure time for each filter set for all images was identical. Arf1-GFP localized to the region between two closely apposed inclusions
(white arrow) and to a thin rim around the inclusion (red arrow) whereas GBF1 was excluded from these regions. *, inclusion. Scale bar=5 mm. (C)
Western blot analysis of siRNA-treated samples. GAPDH was used as a loading control. (D) HeLa cells were depleted of GBF1, BIG1, and/or BIG2 for 3
days, infected with C. trachomatis L2 for 24 hrs, and then labeled with BODIPY FL-Ceramide to visualize SM acquisition by the inclusion. The exposure
time for all images was identical. Dashed red lines demarcate the inclusions. Scale bar=5 mm. (E) HeLa cells were infected with C. trachomatis for
24 hrs, treated with 10 mM BFA or GCA during the last 3 hrs of infection, and then labeled with BODIPY FL-Ceramide to analyze SM acquisition by the
inclusion. The exposure time for all images was identical. Dashed red lines demarcate the inclusions. Scale bar=5 mm. (F) HeLa cells were depleted of
GBF1, BIG1, and/or BIG2 for 3 days, infected with C. trachomatis L2 for 24 hrs, and then analyzed for progeny formation as described in Materials and
Methods. Values (mean 6 standard error) are shown as percentage of control siRNA-treated samples. No significant decrease in progeny formation
was observed. IFU, inclusion forming units.
doi:10.1371/journal.ppat.1002198.g001
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PLoS Pathogens | www.plospathogens.org 5 September 2011 | Volume 7 | Issue 9 | e1002198Figure 2. GBF1 but not BIG1/2 function is required for inclusion membrane stability. (A) HeLa cells were treated with the indicated siRNA
for 3 days, infected with C. trachomatis L2 for 24 hrs, then fixed and stained with antibodies to 14-3-3b (green) to identify the inclusion membrane
and GBF1 (red). Bacteria and host DNA were detected using DAPI (blue). The exposure time for each filter set for all images was identical. White
arrows point to breaks in the inclusion membrane where the bacteria are released into cytoplasm in GBF1-depleted cells. Inclusions formed in BIG1
and/or BIG2 depleted cells remain intact. (B) HeLa cells were depleted of GBF1 for 3 days, infected with C. trachomatis L2 for 24 hrs, then fixed and
stained with antibodies to MOMP (green) to identify bacteria and vimentin (red). Bacteria and host DNA were detected using DAPI (blue). The
exposure time for each filter set for all images was identical. White arrows point to the region on the inclusion that is devoid of vimentin staining and
where bacteria are released into the cytoplasm. N, host nucleus; *, inclusion. MOMP, C. trachomatis major outer membrane protein. Scale bar=5 mm.
doi:10.1371/journal.ppat.1002198.g002
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PLoS Pathogens | www.plospathogens.org 6 September 2011 | Volume 7 | Issue 9 | e1002198Figure 3. CERT and VAP-A are recruited to the inclusion. (A) HeLa cells transfected with CERT-GFP for 18 hrs were left uninfected or infected
with C. trachomatis L2 for 24 hrs. Images shown are maximum intensity projections of confocal z-stacks (0.4-mm slices). N, host nucleus; *, inclusions.
Scale bar=5 mm. (B) HeLa cells transfected with CERT-GFP were infected with C. trachomatis serovar D for 24 hrs and then fixed and stained with
antibodies to IncA (red) to identify the inclusion membrane. Bacteria and host DNA were detected using DAPI (blue). Enlargements (inset) of boxed
regions are shown to the right. *, inclusions. Scale bar=5 mm. (C–E) HeLa cells were transfected with CERT-GFP and HcRedVAP-A for 18 hrs and
infected with C. trachomatis L2 for (C) 2, (D) 8, or (E) 24 hrs. (C) Cells were stained with DAPI to visualize the nascent inclusions (red arrows). (D and E)
Enlargements (inset) of boxed regions are shown to the right. At 8 and 24 hpi, CERT-GFP and HcRedVAP-A colocalize on the inclusion membrane and
exhibit a patchy distribution. Images shown are maximum intensity projections of confocal z-stacks (0.4-mm slices). N, host nucleus; *, inclusions. Scale
bar=5 mm, except with insets from panels B, C, and D where scale bar=2.5 mm.
doi:10.1371/journal.ppat.1002198.g003
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however, inclusions in HPA-12-treated cells showed ,56%
(p,0.001) decrease in fluorescence intensity (Figure 5). Similar
results were observed in control cells treated with D609, an
inhibitor of SMS1 and SMS2 [62,63,64] or with BFA (Figure 5;
p,0.001).
Figure 4. CERT function is required for C. trachomatis replication. HeLa cells were infected with C. trachomatis L2, treated with the indicated
concentration of HPA-12 at 1–24 hpi, and then (A) fixed and stained with antibodies to MOMP (red) and with DAPI (blue) to visualize bacteria or (B)
analyzed for progeny formation. Values (mean 6 standard error) are shown as percentage of DMSO treated samples. Data are representative of 3
independent experiments. ***p,0.001 compared to DMSO treated cells (ANOVA). (C) HeLa cells were transfected with CERT-GFP and HA-CKIc2 for
18 hrs, infected with C. trachomatis L2 for 24 hrs, and then fixed and stained with antibodies to HA (red). The exposure time for each filter set of all
images was identical. Images shown are maximum intensity projections of confocal z-stacks (0.4-mm slices). Ectopic expression of HA-CKIc2 decreased
inclusion size but did not affect CERT-GFP recruitment to the inclusion membrane. Scale bar=5 mm. (D) Western blot analysis of siRNA-treated
samples. GAPDH was used as a loading control. (E) HeLa cells were depleted of CERT for 3 days and then labeled with BODIPY FL-Ceramide to analyze
SM accumulation in the Golgi. The exposure time of all images was identical. CERT depletion reduced SM accumulation in the Golgi. Scale bar=5 mm,
(F) HeLa cells were depleted of CERT for 3 days, infected with C. trachomatis L2 for 24 hrs, and then fixed and stained with antibodies to MOMP
(green) to identify the inclusion. Bacteria and host DNA were detected using DAPI (blue). The exposure time for all images was identical. CERT
depletion reduced inclusion size. Red arrows point to inclusions. Scale bar=5 mm. (G) HeLa cells were depleted of CERT for 3 days, infected with C.
trachomatis L2 and analyzed for inclusion size and progeny formation. Values (mean 6 standard error) are shown as percentage of control siRNA
samples. CERT depletion significantly reduced inclusion size and progeny formation. Data are representative of 2 independent experiments.
***p,0.001 for CERT siRNA-treated cells compared to control siRNA-treated cells (ANOVA). N, host nucleus. IFU, inclusion forming units. Scale
bar=5 mm.
doi:10.1371/journal.ppat.1002198.g004
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possible that CERT is indirectly involved in C. trachomatis infection
based on its role in host SM biosynthesis at the Golgi. In addition
or alternatively, as CERT and VAP-A are also localized at the
inclusion, CERT may be directly involved in C. trachomatis
infection by mediating the transfer of a portion of host ceramide
from the nearby ER directly to the inclusion. We examined the
localization of ceramide in infected cells expressing CERT-GFP
using a ceramide antibody. This antibody does not cross-react with
SM, cholesterol, or other phospholipids under physiologic in vivo
conditions [65]. Ceramide appeared to be highly enriched in the
region adjacent to the inclusion in what is likely to be the
surrounding ER (Figure S5). Importantly, we also found that a
fraction of ceramide localized at the inclusion membrane as
evidence by co-staining with IncA antibodies and Arf1-GFP
(Figure S5A and S5B). Although we found ceramide in close
association with CERT-GFP at the inclusion membrane, ceramide
and CERT-GFP did not overlap on the inclusion membrane
(Figure S5C), possibly reflecting conversion of ceramide to SM and
loss of reactivity with the ceramide antibody. Taken together,
these results indicate that CERT is required for C. trachomatis
replication and that interference with CERT correlates with a
block in the SM acquisition by the inclusion. In addition, the
localization of ceramide during infection suggests that CERT may
be functioning at the Golgi as well as at the inclusion.
CERT transfer activity and ceramide binding are required
for its recruitment to the inclusion
To determine the mechanism of CERT recruitment to the
inclusion, we examined the consequences of inactivating specific
domains of CERT. The ability of CERT to transfer ceramide for
SM biosynthesis requires: (1) interaction with the Golgi membrane
(PI4P) via its PH domain, (2) an interaction with the ER
membrane proteins VAP-A and VAP-B via its FFAT motif, and
(3) the ability to bind ceramide via its START domain [47]. We
were particularly interested in the PH domain, as recent studies
have shown that multiple proteins that regulate PI4P metabolism
are recruited to the inclusion, including OCLR (oculocerebrorenal
syndrome of Lowe protein 1) and the PI4P kinases, PI4KIIa and
to a lesser extent PI4KIIb [40]. The presence of PI4P at the
inclusion combined with our finding that VAP-A colocalizes with
CERT at the inclusion (Figures 3C–3E) raises the possibility that
CERT could be recruited to the inclusion by its interaction with
PI4P and/or with VAP-A.
We examined the localization of two GFP-tagged CERT
mutants: CERT (G67E), which contains a mutation in the PH
domain that prevents CERT from binding PI4P at the Golgi, or
CERT (D324A), which harbors a mutation in the FFAT motif that
prevents CERT from interacting with VAPs at the ER [43,45]
during C. trachomatis infection. In uninfected cells, CERT (G67E)-
GFP is distributed throughout the cell while CERT (D324A)-GFP
is concentrated at the Golgi (data not shown and [45]). As shown
in Figure 6A, both CERT (G67E)-GFP and CERT (D324A)-GFP
localized to the inclusion at 24 hpi in a manner indistinguishable
from CERT-GFP. While CERT-GFP and CERT (D324A)-GFP
show some Golgi localization during infection, none is observed
for CERT (G67E)-GFP (Figure 6A). Co-staining with antibodies to
Calnexin, an ER marker, revealed that although the ER appears
in close proximity to the inclusion, it does not overlap with CERT-
WT, D324A, or G67E at the inclusion (Figure S6). CERT was still
Figure 5. CERT function is required for SM acquisition. (A) HeLa cells were infected with C. trachomatis L2 for 24 hrs, treated with 5 mM HPA-
12 for the last 3 hrs of infection, and then labeled with BODIPY FL-Ceramide to analyze SM accumulation by the inclusion. As a control for decreased
SM acquisition by the inclusion, cells were also treated with 10 mM BFA or 25 mg/ml D609. The exposure time of all images was identical. Dashed red
lines demarcate inclusions. The residual fluorescence likely represents Golgi staining. Scale bar=5 mm. (B) Quantitation of SM acquisition following
treatment with HPA-12, D609, or BFA. Values (mean 6 standard error) are shown as percentage of mean fluorescence intensities relative to DMSO-
treated samples. ***p,0.001 (ANOVA). HPA-12, D609, and BFA-treated cells displayed a significant decrease in fluorescence intensity of the inclusion
and its contents compared to DMSO-treated samples.
doi:10.1371/journal.ppat.1002198.g005
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hamster ovary cells, LY-A, which carries a mutation in the PH
domain of endogenous CERT (G67E) (Figure S3) [43,66]. Despite
the fact that LY-A cells have reduced SM biosynthesis [43,66], SM
acquisition by C. trachomatis inclusions was normal in these cells
(data not shown).
We next tested whether Arf1 activity was required for CERT
recruitment, since Arf1 localizes to the inclusion and since the PH
domains of some lipid transfer proteins, such as FAPPs (four-
phosphate-adaptor protein 2) and OSBP (oxysterol binding
protein), can simultaneously bind PI4P and Arf1 [67]. C.
trachomatis-infected HeLa cells were treated with Exo1, a specific
inhibitor of Arf GTPase activity [68], from 1 to 24 hpi, and
CERT-GFP localization was examined at 24 hpi. Although
quantitation of inclusion size in Exo1 treated cells revealed a
,64% decrease (p,0.001), Exo1 had no effect on CERT
recruitment to the inclusion (Figure 6B). Together, these results
indicate that interaction with PI4P, VAP-A, or Arf1 alone is not
essential for CERT recruitment to the inclusion, though PI4P,
VAP-A, or Arf1 binding may function redundantly or there may
be other determinants within CERT. In addition, CERT-GFP
was still recruited to inclusions in cells treated with GCA, BFA, or
Figure 6. CERT transfer and/or ceramide binding activity are required for its recruitment to inclusions. (A) HeLa cells were transfected
with CERT-GFP, CERT (D324A)-GFP, or CERT (G67E)-GFP, infected with C. trachomatis L2 for 24 hrs, and then fixed and stained with an antibody to
p230 (red) to identify the trans-Golgi. The exposure time for each filter set of all images was identical. Images shown are maximum intensity
projections of confocal z-stacks (0.4-mm slices). Mutation of the PI4P binding (G67E) or VAP-A binding (D324A) domains did not affect CERT-GFP
recruitment to the inclusion. Scale bar=5 mm. (B) HeLa cells expressing CERT-GFP were infected with C. trachomatis L2, treated with 50 mM Exo1 (Arf1
inhibitor) for 1–24 hpi, and then fixed and stained with antibodies to MOMP (red) to identify bacteria. The exposure time for each filter set of all
images was identical. Images shown are maximum intensity projections of confocal z-stacks (0.4-mm slices). CERT-GFP localization to the inclusion was
unaffected by Arf1 inhibition. Scale bar=5 mm. (C) HeLa cells expressing CERT-GFP were infected with C. trachomatis L2, treated with 5 mM HPA-12
for 1–24 hpi, and then fixed and stained with antibodies to MOMP (red) to identify bacteria or to p230 (red) to identify the trans-Golgi. The exposure
time for each filter set of all images was identical. Inhibition of CERT transfer and/or ceramide binding activity by HPA-12 treatment resulted in losso f
CERT accumulation on the inclusion membrane. Images shown are maximum intensity projections of confocal z-stacks (0.4-mm slices). Scale
bar=5 mm. N, host nucleus; *, inclusion.
doi:10.1371/journal.ppat.1002198.g006
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indicating that GBF1 function, vesicular trafficking, and microtu-
bules are not required for CERT recruitment.
To test whether CERT lipid transfer activity and/or ceramide
binding is required for CERT recruitment to the inclusion, we
treated cells expressing CERT-GFP with 5 mM HPA-12 from 1 to
24 hpi. In control experiments, HPA-12 treatment did not affect
CERT-GFP localization to the Golgi region in uninfected cells
(data not shown). In C. trachomatis-infected cells exposed to HPA-
12, the patchy distribution of CERT-GFP was lost from the
inclusion (Figure 6C, top row), although CERT-GFP was still
present in the Golgi surrounding the inclusion, as evidenced by
colocalization with p230, a trans-Golgi marker (Figure 6C, bottom
row). These results indicate that ceramide binding and/or the
transfer activity of CERT is required for its recruitment to the
inclusion.
SMS1 and SMS2 are recruited to distinct compartments
at the inclusion
Since CERT cannot directly transfer SM [44], we considered
the possibility that SMS1 or SMS2 are directly recruited to the
inclusion, where they could synthesize SM following ceramide
transfer to the inclusion by CERT. In uninfected cells, both SMS1
and SMS2 are found at the trans-Golgi while SMS2 also localizes
to the plasma membrane (Figure S7 and [46,69]).
We examined the localization of CERT-GFP and C-terminally
3xFLAG-tagged SMS1/SMS2 or SMS1-V5 and C-terminally
3xFLAG-tagged SMS2 during C. trachomatis infection at 24 hpi. In
uninfected cells, C-terminally 3xFLAG-tagged SMS1 and
3xFLAG-tagged SMS2 were located in close apposition to
CERT-GFP at the Golgi (Figure 7A). In infected cells, C-
terminally 3xFLAG-tagged SMS1 primarily localized to the
fragmented Golgi surrounding the inclusion and displayed no
overlap with CERT-GFP at the inclusion (Figure 7A). In contrast,
C-terminally 3xFLAG-tagged SMS2 localized to both the
fragmented Golgi as well as to the inclusion membrane, where it
exhibited a distinct punctate pattern that partially overlapped with
CERT-GFP (Figure 7A). Localization of SMS2 to the inclusion
membrane was confirmed by co-staining infected cells expressing
SMS2-V5 with antibodies to IncA; inclusion-membrane localized
SMS2-V5 appeared to partially overlap with IncA whereas no
overlap was seen between IncA and SMS1-V5 (Figure 7B).
To further distinguish between inclusion membrane versus
Golgi localization, we examined the distribution of SMS1-V5 or
SMS2-V5 in infected HeLa cells following disruption of the Golgi
by BFA or by Nocodazole. As shown in Figure 7C, exposure of C.
trachomatis-infected cells to either BFA or to Nocodazole caused
SMS1-V5 to disperse throughout the cell while SMS2-V5
remained primarily associated with the inclusion, where a rim-
like staining was observed. These results indicate that SMS2 is
tethered to the inclusion during infection whereas SMS1 is
primarily associated with the Golgi around the inclusion. In
addition, SMS2 recruitment to the inclusion is independent of
microtubules and of Arf1/GBF1-dependent vesicular trafficking.
The mechanism by which SMS1 or SMS2 localize to the trans-
Golgi has not yet been elucidated. However, it was recently shown
that SMS2 is palmitoylated at the carboxyl terminus and that this
modification plays a role in targeting SMS2 to the plasma
membrane [69]. We therefore tested whether SMS2 recruitment
to the inclusion required palmitoylation by examining the
localization of a C-terminally 3xFLAG-tagged SMS2 construct
in which all four of the potential palmitoylation sites were mutated
(C331, 332, 343, 348A) [69]. Although this mutant displays a
decrease in PM distribution (data not shown and [69]), it was
recruited to the inclusion in a similar fashion as C-terminally
3xFLAG-tagged SMS2 wild-type (Figure S7). This result suggests
that palmitoylation is not required for SMS2 recruitment to the
inclusion.
SMS1 and SMS2 are required for C. trachomatis
replication
Both SMS1 and SMS2 are required for host SM production,
however their relative contributions to subcellular SM levels are
distinct, with SMS1 generating the bulk of SM at the Golgi while
SMS2 is responsible for SM biosynthesis at the plasma membrane
[46,56]. Our observation that SMS2 but not SMS1 is recruited to
the inclusion membrane prompted us to determine their relative
contributions to infection. Cells were depleted of SMS1 or SMS2
by siRNA [56] for 72 hrs and subsequently infected with C.
trachomatis for 24 hrs. The efficiency of depletion was verified by
western blot analysis in cells expressing C-terminally 3xFLAG-
tagged SMS1 and 3xFLAG-tagged SMS2 (Figure 8A). Loss of
SMS1 activity was confirmed by demonstrating decreased
accumulation of BODIPY FL-Ceramide and BODIPY FL-SM
at the Golgi apparatus (Figure 8B) [56]. Depletion of either SMS1
or SMS2 resulted in a significant reduction in relative inclusion
size and progeny formation (Figures 8C–D). These results
demonstrate that both SMS1 and SMS2 contribute to C.
trachomatis replication and inclusion growth. Our results support
the hypothesis that at least a portion of SM acquired by C.
trachomatis may be directly synthesized on the inclusion membrane.
In addition, SM synthesized at the nearby Golgi by SMS1 and
SMS2 transported by a BFA-insensitive pathway may also
contribute to replication.
Discussion
Different pathogens have evolved a variety of unique strategies
to establish a protective intracellular niche in which to replicate
and to obtain essential nutrients from the host. For example,
Legionella pneumophila replicates within a vacuole that is closely
associated with the ER, while Salmonella and Mycobacteria species
replicate within compartments that have characteristics of
endosomes [70]. Chlamydiae are among the few known pathogens
that occupy an exocytic compartment from which they acquire
host-derived nutrients, including SM and cholesterol [6,9,10,
11,12,13,14]. While previous work supports a role for canonical
vesicular trafficking in the acquisition of SM by Chlamydia from the
host, it has remained a mystery as to why inhibitors of vesicular
trafficking have no effect on Chlamydia replication, given that host
SM biosynthesis is necessary for bacterial replication [6,12]. Here,
we demonstrate that C. trachomatis co-opts key proteins involved in
both vesicular and non-vesicular lipid trafficking pathways to
acquire SM for distinct roles during infection, providing an
intriguing explanation for this apparent paradox. We found that C.
trachomatis recruits CERT, its ER binding partner VAP-A, and SM
synthases to establish an on-site SM biosynthetic factory at or near
the inclusion that is critical for C. trachomatis replication. In
addition, we show that C. trachomatis co-opts the function of GBF1,
a regulator of Arf1-dependent vesicular trafficking within the early
secretory pathway, to further provide SM. This source of SM
contributes to inclusion membrane growth and stability but is not
essential for bacterial replication.
We found that depletion or inhibition of CERT significantly
impaired production of infectious progeny and SM acquisition.
While these treatments decrease SM biosynthesis and would thus
be expected to affect C. trachomatis replication, unexpectedly and
most remarkably, we found that CERT was recruited to the
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mutually exclusive mechanisms by which CERT could promote
SM acquisition during infection (Figure 9). CERT could transport
ceramide directly from the ER to the inclusion, where this lipid
would serve as a substrate for inclusion membrane localized
SMS2, allowing SM biosynthesis to proceed on the inclusion
membrane (Figure 9, step A). SM would then be transferred from
the inclusion membrane to intracellular RBs. Alternatively, or in
addition, by virtue of its ability to bind to the ER and to the Golgi,
CERT could help to coordinate recruitment of these organelles to
the inclusion (Figure 9, step B). This process would bring the trans-
Golgi localized SMS1 and SMS2 in close proximity to the ER and
to the inclusion, thereby promoting efficient SM synthesis in the
vicinity of the inclusion. Since CERT cannot transport SM [44], it
is likely that this source of SM is subsequently transferred to the
inclusion by a BFA-insensitive vesicular trafficking pathway. It is
also possible that SM could be transferred from the Golgi at MCS
to the inclusion by one of several mechanisms involving non-
vesicular lipid exchange between membranes, such as transient
hemifusion and/or stochastic collision with the Golgi [71].
Our results suggest that both SMS1 and SMS2 contribute to
infection. The involvement of SMS1 was not surprising, since this
enzyme is responsible for the bulk of total host cell SM biosynthesis
(60–80%) [46,56]. However, our finding that SMS2 was localized
to the inclusion membrane and played a role in intracellular
growth was unexpected since SMS2 participates primarily in SM
biosynthesis at the plasma membrane and plays a minor role in
overall host cell SM biosynthesis (20–40%) [46,56]. In contrast to
SMS1, inclusion membrane localized SMS2 and CERT are not
disrupted by BFA, GCA, or Nocodazole, which may explain why
bacterial replication is not affected by these drugs. We note that it
is difficult by current methods to demonstrate that SM is
synthesized directly on the inclusion, since SM can also arrive
via vesicular trafficking [46,56]. We speculate that by preferen-
tially recruiting SMS2 over SMS1 during infection, C. trachomatis
ensures a source of SM for itself without placing a huge burden on
the host’s ability to synthesize SM since SMS1 would still be active
at the Golgi. Future studies will be required to unravel how SMS2
is recruited to the inclusion membrane.
How is CERT, a multi-domain protein, recruited to the
inclusion? Although the recruitment of CERT to Golgi and ER
membranes requires the PH and FFAT domains, respectively [47],
we found that only the ceramide binding and/or ceramide transfer
activity of CERT is required for its recruitment to the inclusion.
While CKIc2-induced phosphorylation of CERT inhibits its
activity, CERT was still recruited to the inclusion, presumably
because CERT is still able to bind ceramide. On the other hand,
exposure to HPA-12 prevented CERT recruitment to the
inclusion, possibly through its known ability to inhibit interaction
of the START domain with membranes in vitro [60]. An
alternative scenario is that HPA-12 binding to CERT could alter
its ability to bind PI4P, VAP-A, or potentially a bacterial factor at
the inclusion membrane through steric hindrance or conforma-
tional change. We favor the hypothesis that CERT binds to
ceramide at the ER, prior to its recruitment to the inclusion, and
subsequently interacts with the inclusion by an as yet to be
identified bacterial or host protein. It is also possible that a small
amount of ceramide and/or VAP-A may initially be incorporated
into the inclusion membrane from either the plasma membrane
during endocytosis or by fusion with the ER or ER-derived vesicles
containing ceramide, which would then promote CERT recruit-
ment. These initial events could then set up an amplification
mechanism for subsequent ceramide transfer and SM synthesis.
Further studies are needed to determine whether CERT transfer
activity or ceramide binding alone is necessary for its recruitment
to the inclusion, and whether either of these functions cooperates
with a bacterial protein present in the inclusion membrane.
It was surprising that PI4P binding was not required for CERT
recruitment to the inclusion, given the recent observation that
PI4P binding is necessary and sufficient to recruit the PH domain
of OSBP [40]. However, it should be noted that those studies were
performed with only the PH domain of OSBP whereas our studies
were performed in the context of the entire CERT protein
containing a single point mutation (G67E) that abolishes PI4P
binding. It is likely that there are multiple localization signals for
CERT recruitment to the inclusion.
The dispensable requirement of PI4P binding for CERT
recruitment to the inclusion likely explains why inclusions still
form in LY-A cells expressing CERT (G67E) and why CERT still
localizes to the inclusion in these cells. It is worth noting that
recombinant CERT (G67E) is still able to transfer ceramide in an
in vitro assay [45], suggesting that although SM synthesis is reduced
in the LY-A cell line due to the inability of CERT to bind the
Golgi and transfer ceramide [43,66], SM synthesis may proceed at
the inclusion because this specialized compartment has access to
ceramide via CERT and at least one SMS isoform.
While the role of CERT in ceramide transfer and SM
biosynthesis is clearly established, we cannot rule out the possibility
CERT may have other functions in host cells relevant to Chlamydia
infection. Previous work has suggested that there is an intimate
association of the ER or ER proteins with the chlamydial inclusion
[57,58]. It is possible that CERT and VAP-A together may be
important for coordinating ER-inclusion membrane contact sites.
These membrane contact sites could be important for the inclusion
to obtain other essential lipids or nutrients for growth. Although
loss of CERT function in individual cells has no effect on cell
survival [43,66], knockout of CERT in mice is embryonic lethal as
a result of severe defects in both the ER and mitochondria
Figure 7. SMS1 and SMS2 localization in C. trachomatis infected cells. (A) HeLa cells co-transfected for 18 hrs with CERT-GFP and C-terminally
3xFLAG-tagged SMS1/SMS2 (upper 2 rows) or SMS1-V5 and C-terminally 3xFLAG-tagged SMS2 (bottom row) were infected with C. trachomatis L2 for
24 hrs, and then fixed and stained with antibodies to FLAG (red) and/or to V5 (green). Single channel images of uninfected cells are shown to the
right. Enlargements of the boxed regions (inset) in infected samples are shown to the right of infected set. The exposure time for each filter set of all
images was identical. Images shown are maximum intensity projections of confocal z-stacks (0.4-mm slices). CERT and SMS1 localization at the
inclusion are distinct while CERT and SMS2 partially overlap. SMS2 localization partially overlaps with SMS1 around the inclusion, however SMS2 also
localizes to the inclusion. At longer exposure times, SMS2 plasma membrane localization is evident. Scale bar=5 mm, except the insets where scale
bar=2.5 mm. (B) HeLa cells transfected with SMS1-V5 (green) or SMS2-V5 (green) infected with C. trachomatis serovar D for 24 hrs and then fixed and
stained with antibodies to IncA (red) to identify the inclusion membrane. Enlargements of the boxed regions (inset) are shown to the right. Images
represent a single z slice from confocal images. The exposure time for each filter set for all images was identical. SMS2 but not SMS1 partially overlaps
with IncA on the inclusion. Scale bar=5 mm, except the insets where scale bar=2.5 mm. (C) HeLa cells transfected for 18 hrs with CERT-GFP, SMS1-V5,
or SMS2-V5 were infected with C. trachomatis L2, treated with 10 mM BFA or Nocodazole for 1–24 hpi, and then fixed and stained with antibodies to
V5 (green) and to p230 (red) to identify the trans-Golgi. BFA and Nocodazole disrupted SMS1 localization around the inclusion but had no effect on
SMS2 or CERT localization at the inclusion. Images represent a single z slice from confocal images. Scale bar=5 mm. N, host nucleus; *, inclusion.
doi:10.1371/journal.ppat.1002198.g007
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CERT have a short lifespan and show enhanced susceptibility to
oxidative stress [73].
Our studies provide further insights into the mechanism of BFA-
sensitive SM acquisition. While it was previously suggested that
Chlamydia occupies a post Golgi compartment with the prediction
that trafficking from the trans-Golgi would be essential, our results
demonstrate that acquisition of SM by Chlamydia requires Arf1
activation within the cis-Golgi but not Arf1 activation within the
trans-Golgi (Figure 9, step C), suggesting that Chlamydia is not
necessarily co-opting the entire organelle. Loss of SM acquisition
following inhibition of GBF1 function correlated with a loss of
inclusion membrane integrity and alterations in the localization of
actin and vimentin cytoskeletal components surrounding the
inclusion (Figure 9, step D). Whether the loss of inclusion integrity
is a direct or indirect consequence of the collapse of the closely
associated cytoskeletal cage or whether it results from the loss of
SM acquisition, as suggested by Beatty and coworkers [15],
remains to be determined. Of note, GCA was not reported to
affect the stability of serovar E inclusions [15]; however, this
disparity may reflect strain differences.
We observed that GBF1 and Arf1 have little overlap at the
inclusion membrane during infection even though they extensively
colocalize at the Golgi surrounding the inclusion. This observation
could reflect a transient and dynamic interaction at the inclusion.
Alternatively, we favor the hypothesis that GBF1 activates Arf1 at
the Golgi and then Arf1-vesicles containing SM traffic to and fuse
with the inclusion. Under these circumstances, GBF1-dependent
activation of Arf1 at the Golgi rather than at the inclusion would
be important, which could explain why there is little colocalization
of these proteins at the inclusion. Consistent with this notion, we
found that inhibition of GBF1 activity resulted in a loss of inclusion
localized Arf1, except at the region of abutting inclusion
membranes. This finding suggests that GBF1 is required for
Arf1 recruitment to the outer region of the inclusion but not for
Arf1 maintenance at closely apposed inclusions. We are currently
investigating the role of Arf1 at this region.
Recent studies have revealed that Arf1 and GBF1 also play
important roles in lipid droplet biogenesis [74,75]. As lipid
droplets are translocated into the lumen of the inclusion [76,77],
interference with Arf1 and/or GBF1 function could also affect
Chlamydia interaction with lipid droplets. Notably, GBF1 coloca-
lizes with Lda3 (unpublished results), a chlamydial protein that
localizes to lipid droplets [77].
Chlamydia now joins the growing list of pathogens that subvert
GBF1 or Arf1 function to establish an intracellular replicative
niche, including poliovirus, coxsackievirus, coronavirus, hepatitis
C virus, and Legionella pneumophila [26]. In contrast to these
pathogens where depletion or inhibition of GBF1 by BFA
significantly impairs replication, our findings demonstrate that
GBF1 is more important for establishing a stable intracellular
niche in which C. trachomatis replicates. Both poliovirus and
coxsackievirus encode a protein (3A) that binds to and co-opts
GBF1 function, while L. pneumophila secretes into the cell RalF, an
Arf GEF, that regulates Arf1 localization to the L. pneumophila-
Figure 8. SMS1 and SMS2 contribute to C. trachomatis
replication. (A) Western blot analysis of siRNA-treated samples.
GAPDH was used as a loading control. (B) HeLa cells were depleted
of SMS1 or SMS2 for 3 days and then labeled with BODIPY FL-Ceramide
to analyze SM accumulation in the Golgi. The exposure time of all
images was identical. SMS1 but not SMS2 depletion reduced BODIPY FL
lipid accumulation in the Golgi. Scale bar=5 mm. (C and D) HeLa cells
were depleted of SMS1 or SMS2 for 3 days, infected with C. trachomatis
L2 for 24 hrs, and then fixed and stained with an antibody to MOMP
(red). Bacteria and host DNA were detected using DAPI (blue). (D) SMS1
and SMS2-depleted cells were analyzed for inclusion size and progeny
formation. Values (mean 6 standard error) are shown as percentage of
control siRNA samples. SMS1 and SMS2 depletion reduced inclusion
size and production of infectious progeny. Data are representative of 2
independent experiments. ***p,0.001, all samples compared to control
siRNA treatment (ANOVA). N, host nucleus; red arrows point to
inclusions. IFU, inclusion forming units. Scale bar=5 mm.
doi:10.1371/journal.ppat.1002198.g008
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the inclusion membrane, it is possible that GBF1 communicates
indirectly with the inclusion through a variety of host proteins or
lipids that have been shown to bind GBF1 and that localize at or
near the inclusion, including Rab1 [80], PI4P [81], and the Golgi
matrix proteins, golgin 84 and p115 [26]. It will be important to
determine whether the alterations in the actin and vimentin
cytoskeleton during infection are directly or indirectly modulated
by GBF1.
In summary, we show that C. trachomatis hijacks components of
both vesicular and non-vesicular lipid trafficking pathways for SM
acquisition, and that the SM obtained from these pathways is
utilized in different ways by the pathogen. We hypothesize that
SM acquired by CERT-dependent transport of ceramide and
subsequent conversion to SM is necessary for C. trachomatis
replication whereas SM acquired by the GBF1-dependent
pathway is essential for inclusion growth and stability. Together,
these observations provide an intriguing explanation for why
inhibition of vesicular trafficking alone fails to affect intracellular
replication. Moreover, our results describe the first example of a
bacterial pathogen to co-opt CERT and reveal a novel strategy by
which this organism creates its own SM biosynthetic factory. This
work has identified novel targets that may prove useful in
combating Chlamydia infections.
Materials and Methods
Reagents
D609 was purchased from Calbiochem. Brefeldin A, Nocoda-
zole, and Exo1 were purchased from Sigma. Golgicide A (GCA)
was kindly provided by D. Haslam (Washington University School
of Medicine, St. Louis, MO). BODIPY FL C5 Ceramide was
obtained from Molecular Probes. Construction of Arf1-GFP, Arf1-
mCherry, and GFP-GBF1 were previously described [82,83].
CERT-GFP, CERT (D324A)-GFP, CERT (G67E)-GFP, HcRed-
VAP-A, HA-CKIc2, and HPA-12 were kind gifts from K. Hanada
(National Institute of Infectious Disease, Tokyo) and have been
previously described [45,59]. C-terminally V5-tagged SMS1 and
SMS2 constructs were kind gifts from J. Holthuis (Utrecht
University) and have been described previously [46]. C-terminally
3xFLAG-tagged SMS1 and SMS2 constructs were kind gifts from
M. Tani (Kyushu University) and have been previously described
Figure 9. Model for the role of CERT and GBF1 in C. trachomatis infection. (A) CERT and VAP-A are recruited to the inclusion. CERT transfers
ceramide from the ER to the inclusion. Inclusion membrane localized SMS2 converts ceramide to SM, which accumulates on the inclusion membrane
and on RBs. (B) Alternatively, or in addition, CERT promotes recruitment of ER-Golgi MCS to the vicinity of the inclusion, promoting efficient SM
synthesis near the inclusion. SM is then transferred to the inclusion by a BFA-insensitive pathway. (C) GBF1-dependent activation of Arf1 mediates
vesicular trafficking of SM-containing vesicles to the inclusion for membrane growth and stability. (D) GBF1 activity contributes to the arrangement of
the actin and vimentin networks around the inclusion for additional stability. CERT is essential for bacterial replication whereas GBF1 is important for
inclusion membrane growth and stability. MCS, membrane contact site; TGN, trans-Golgi network.
doi:10.1371/journal.ppat.1002198.g009
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Unless otherwise indicated, the following concentrations of
inhibitors were used: 5 mM HPA-12, 25 mg/ml D609, 10 mM
GCA, 10 mM BFA, 10 mM Nocodazole, and 50 mg/ml Exo1.
Antibodies were obtained from the following sources: mouse anti-
Chlamydia FITC conjugate (Meridian Diagnostics), goat anti-C.
trachomatis MOMP (Cortex Biochem), mouse anti-GAPDH
(Chemicon), mouse anti-GBF1 (BD Transduction Laboratories),
rabbit anti-BIG1 (Santa Cruz), rabbit anti-BIG2 (Bethyl Labora-
tories, Inc.), chicken anti-CERT (Sigma), rabbit anti-14-3-3b
(Santa Cruz), mouse anti-vimentin (Sigma), mouse anti-FLAG
(Sigma), rabbit anti-V5 (Sigma), mouse anti-HA (Covance), rabbit
anti-p58 (Sigma), mouse anti-ceramide IgM (Clone15B4), rabbit
anti-calnexin (Cell Signaling), rabbit anti-goat IgG horseradish
peroxidase (HRP) (Calbiochem), goat anti-rabbit IgG HRP
(Amersham Biosciences), goat anti-mouse HRP (Amersham
Biosciences), donkey anti-goat Alexa 594 (Molecular Probes),
donkey anti-goat Alexa 488 (Molecular Probes), chicken anti-
mouse 594 (Molecular Probes), goat anti-mouse IgG1 Alexa 594
(Molecular Probes), donkey anti-goat Alexa 488 (Molecular
Probes), Texas red-conjugated donkey anti-chicken IgY (Jackson
Laboratories), and donkey anti-rabbit Alexa 488 (Molecular
Probes). Texas red-conjugated phalloidin was obtained from
Molecular Probes. Mouse anti-IncA antibodies were kind gifts
from T. Hackstadt (Rocky Mountain Laboratories), D. Rockey
(Oregon State University), and G. Zhong (University of Texas
Health Science Center at San Antonio). All siRNAs, including
non-targeting negative controls, were obtained from Dharmacon:
Human GBF1 (J-019783-06), human BIG1 (D-012207-02, D-
012207-03), and human BIG2 (MQ-012208-01) and have been
previously described [33,84]. Human SMS1 and SMS2 siRNA
sequences have been previously described [56]. Human CERT
siRNA was performed using siGENOME SMARTpool.
Cell culture and C. trachomatis propagation
HeLa 229 cells and L929 cells were obtained from ATCC and
passaged as previously described [85]. LY-A and LY-A/hCERT
cells were obtained from RIKEN BRC through the National Bio-
Resource Project of MEXT, Japan and have been previously
described [43,66]. CHO cells were maintained at 37uC with 5%
CO2 in Ham’s F12 containing 10% fetal bovine serum (FBS). C.
trachomatis serovar L2 (LGV 434) and D (UW3-Cx) were
propagated in L929 cells. C. trachomatis EBs were harvested from
infected cells and purified using a Renografin step-gradient as
described [86]. Unless otherwise indicated, experiments were
performed with serovar L2.
Immunofluorescence studies
Cells were grown on glass coverslips in 24-well plates and
infected at a multiplicity of infection (MOI) of approximately 1–5
with C. trachomatis as described in the text. For expression of tagged
constructs, cells were transfected with the indicated plasmid
constructs using Effectene (Invitrogen) for 18 hrs prior to infection,
following manufacturer’s instructions. Cells were fixed in 4%
paraformaldehyde (PFA) or methanol and stained with the
appropriate antibodies. For anti-GBF1, anti-14-3-3b, anti-
MOMP, anti-HA, anti-ceramide, anti-calnexin, anti-p58, and
anti-V5 staining, cells were permeabilized with 0.05% saponin/
0.2% bovine serum albumun (BSA) in phosphate buffered saline
(PBS) for 30 minutes and blocked with 0.2% BSA/PBS for
30 minutes. For anti-CERT staining, cells were permeabilized
with 0.5% Triton X-100/PBS for 3 minutes and blocked with 1%
BSA/PBS for 20 minutes. For phalloidin staining, cells were
permeabilized with 0.2% Triton/PBS and blocked with 1% BSA/
PBS for 1 hr. For anti-vimentin and anti-IncA staining, cells were
post-fixed in methanol for 5 minutes and blocked in 2% BSA/PBS
for 1 hr. Cells were incubated with the appropriate primary and
fluorophore-tagged secondary antibodies for 1 hr each, followed
by washing 3 times in PBS. Anti-FLAG staining was performed as
previously described [69]. Coverslips were mounted in Vectashield
mounting media containing DAPI (Vector Laboratories) to
identify bacteria and host cell nuclei. Images were acquired under
20, 40 or 1006 oil objective using a Nikon Eclipse TE2000-E
fluorescence microscope with Simple PCI imaging software
(Compix, Inc.) or acquired under 1006oil objective using Nikon
TE2000-PFS spinning disk confocal inverted microscope with
Nikon Elements software. For each set of experiments, the
exposure time for each filter set for all images was identical.
Images were processed with Adobe Photoshop CS, Nikon
Elements, or Imaris Software.
Immunoblot analysis
Cells were lysed in lysis buffer (50 mM Tris HCl, pH 7.5,
150 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 1% sodium
deoxycholate, 1 mM sodium orthovanadate, 1 mM sodium
fluoride, 1 mM okadaic acid, and Complete protease inhibitors
(Roche Diagnostics)). After centrifugation at 20,8006 g for
5 minutes to remove cell debris, the supernatants were transferred
to fresh tubes. Proteins were separated on 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and
transferred to 0.45-mm pore Trans-blot nitrocellulose membranes
(BioRad Laboratories). Membranes were blocked with 5% milk
and probed with the indicated antibodies. Proteins were detected
by enhanced chemiluminescence (ECL) (Amersham Biosciences)
according to the manufacturer’s protocol.
RNAi studies
HeLa cells grown in 6-well plates were transfected with specific
or control siRNAs according to manufacturer’s protocol. At 72 hrs
post transfection, cells were infected with C. trachomatis for 1 hr and
then incubated for an additional 24 hrs. Knockdown efficiency
was measured by western blot analysis for endogenous protein, or
in the case of SMS1 and SMS2, knockdown efficiency was
determined using HeLa cells expressing C-terminally 3xFLAG-
tagged SMS constructs as previously described [56]. Knockdown
efficiency for SMS1 was also determined using BODIPY FL-
Ceramide (see below).
Quantitation of primary inclusion formation, inclusion
size, inclusion membrane disruption, and production of
infectious progeny
HeLa cells were incubated with the indicated siRNA for 3 days
and subsequently infected with C. trachomatis (MOI of 1–5) for
24 hrs. For drug treated samples, HeLa cells were infected with C.
trachomatis for 1 hr and then incubated for an additional 23 hrs in
the presence of the indicated drug. To quantify primary inclusion
formation, cells were fixed and processed by immunofluorescence
and processed as described below. To quantify production of
infectious progeny, infected cells were scraped into media, lysed
with sonication, and 5-fold serial dilutions were used to infect fresh
HeLa monolayers that had been plated on coverslips for 24 hrs.
For assessment of drug effects on bacterial viability and
internalization, progeny was harvested from DMSO treated
samples and left untreated or treated with the various inhibitors
during the 1 hr infection of fresh HeLa monolayers. Cells were
then washed free of the inhibitor and incubated for an additional
24 hrs. Inclusions were visualized by immunofluorescence with
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mouse anti-Chlamydia FITC conjugate. Images were analyzed
using MetaMorph software (Molecular Devices, Sunnyvale, CA)
from a minimum of 10 fields per sample. The relative inclusion
forming units (IFUs) were expressed as a percentage of control
siRNA or DMSO controls. The data is presented as mean 6
standard error. To quantify the relative size of inclusions,
approximately 200–350 cells were counted from 7–10 fields, the
inclusion area analyzed by Metamorph using the mean area
function, and the data is normalized to the percent area of control
siRNA or DMSO-treated cells. To quantify inclusion disruption,
approximately 350 cells were scored for apparent breaks in the
inclusion membrane by staining with 14-3-3b and for concomitant
release of bacteria into the cytosol. The data is normalized to
percentage of similarly scored control or DMSO-treated cells.
Sphingomyelin accumulation assay
HeLa cells were infected with C. trachomatis for 21 hrs and then
treated with the indicated drug for an additional 3 hrs. At 24 hpi,
live cells were then incubated for 30 minutes in serum-free MEM
containing 1 mM BODIPY FL-Ceramide (Molecular Probes)
complexed with 0.034% defatted bovine serum albumin (dfBSA)
in MEM at 4uC in the dark. Cells were washed 3 times with serum
free MEM and back exchanged with MEM/0.34% dfBSA for
1 hr. Cells were immediately visualized by fluorescence micros-
copy under a 406 objective. To assess SM accumulation in the
Golgi upon depletion of CERT or SMS1, BODIPY FL-Ceramide
labeling was performed at 72 hrs post siRNA treatment and
fluorescence intensity in the Golgi region of siRNA-treated
samples was compared to control siRNA. To assess SM
accumulation by the inclusion upon depletion and inhibition of
GBF1 and BIGs, cells were treated with the appropriate siRNA for
72 hrs, infected with L2, and BODIPY FL-Ceramide labeling was
performed at 24 hpi. For quantitation of SM accumulation in the
inclusion, mean fluorescence intensity of the inclusion was
determined by defining regions of interest within the inclusion
and dividing by the mean fluorescence intensity of the nucleus,
which remained constant with all drug treatments. At least 5 fields
were examined, and values were obtained from a total of 10–15
inclusions.
Statistical analysis
Data represented the mean 6 standard error of n experiments.
Statistical analysis was performed using the software program
Instat. The significance between groups was determined by
ANOVA. A p value less than 0.05 was considered to be statistically
significant.
Gene IDs
Arf1 (GeneID 375), GBF1 (GeneID 8729), BIG1 (GeneID
10565), BIG2 (GeneID 10564), CERT (GeneID 10087), VAP-A
(GeneID 9218), SMS1 (GeneID 259230), and SMS2 (GeneID
166929).
Supporting Information
Figure S1 Inhibition or depletion of GBF1 but not BIGs
reduces SM acquisition and inclusion size. Quantitation of
SM acquisition by the inclusion following (A) depletion of GBF1,
BIG1, and/or BIG2 and (B) inhibition of GBF1 with 10 mM GCA
or BFA. Values (mean 6 standard error) are shown as percentage
of mean fluorescence intensities relative to DMSO or control
siRNA-treated samples. ***p,0.001 (ANOVA). Inhibition or
depletion of GBF1 decreased the inclusion fluorescence intensity
compared to DMSO or control siRNA-treated samples, respec-
tively. (C) HeLa cells were depleted of GBF1, BIG1, and/or BIG2
for 3 days, infected with C. trachomatis L2 for 24 hrs, and then fixed
and stained with an antibody to MOMP (green) to identify
bacteria. Bacteria and host DNA were detected using DAPI (blue).
The exposure time for each filter set for all images was identical.
N, host nucleus; red arrows point to inclusion. Scale bar=5 mm.
(D) Quantitation of inclusion size in GBF1 and BIG1/2 depleted
cells. Values (mean 6 standard error) are shown as percentage of
control siRNA samples. GBF1 depletion reduced inclusion size.
Data are representative of 3 independent experiments.
***p,0.001, all samples compared to control siRNA treatment
(ANOVA). IFU, inclusion forming units.
(TIF)
Figure S2 Inhibition of GBF1 alters the actin and
vimentin structures surrounding the inclusion. (A) HeLa
cells were infected with C. trachomatis L2, treated with 10 mM BFA
or GCA for 1–24 hpi, and then fixed and stained with antibodies
to 14-3-3b (green) to identify the inclusion membrane and GBF1
(red). Bacteria and host DNA were detected using DAPI (blue).
The exposure time for each filter set for all images was identical.
The inclusion membrane is discontinuous (white arrows) and
bacteria are released into the cytoplasm upon exposure to GCA or
BFA. Note the compact peri-nuclear localization of GBF1 upon
GCA and BFA treatment. (B–C) HeLa cells were infected with C.
trachomatis L2, treated with 10 mM GCA for 1–24 hpi, and then
fixed and stained with antibodies to MOMP (green) to identify
bacteria and (B) vimentin (red) or (C) with phalloidin to stain actin
(red). The exposure time for each filter set for all images was
identical. Images represent a single z slice from confocal images.
White arrows point to a region around the inclusion that is devoid
of vimentin or actin and where bacteria are released into the
cytoplasm. N, host nucleus; *, inclusion. Scale bar=5 mm.
(TIF)
Figure S3 CERT (G67E) is recruited to inclusions in LY-
A cells. LY-A mutant cell line expressing CERT (G67E) or LY-A
cell line complemented with wild type human CERT (LY-A/
hCERT) were infected with C. trachomatis L2 for 24 hrs and then
fixed and stained with antibodies to CERT (red) and MOMP
(green). The exposure time for each filter set for all images was
identical. Images shown are maximum intensity projections of
confocal z-stacks (0.4-mm slices). *, inclusion; Scale bar=5 mm.
(TIF)
Figure S4 CERT recruitment to the inclusion is not
dependent on GBF1 function. (A) HeLa cells transfected with
CERT-GFP were infected with C. trachomatis L2 for 2 hrs in the
absence or presence of 10 mM GCA and stained with an antibody
to the p58 (red), an ER-Golgi intermediate compartment marker.
Bacteria and host DNA were detected using DAPI (blue).
Enlargements of the boxed region (inset) are shown to the right.
GCA did not prevent recruitment of CERT to the nascent
inclusion. Scale bar=5 mm, except in the inset, where scale
bar=2.5 mm. (B) HeLa cells transfected with CERT-GFP were
left uninfected or infected with C. trachomatis L2 for 8 or 24 hrs in
the presence of 10 mM GCA at 1–24 hpi. Images shown are
maximum intensity projections of confocal z-stacks (0.4-mm slices).
CERT-GFP recruitment to the inclusion was not dependent upon
GBF1 function at mid or late times during infection. N, host
nucleus. Red arrows point to inclusions. Scale bar=5 mm. (C)
HeLa cells co-expressing CERT-GFP and Arf1-RFP were left
uninfected or infected with C. trachomatis L2 for 8 hrs. Images
shown are maximum intensity projections of confocal z-stacks (0.4-
mm slices). CERT-GFP localizes to both the Golgi and the
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inclusions. Scale bar=5 mm.
(TIF)
Figure S5 Ceramide localizes on and around the
inclusion. (A) HeLa cells were infected with C. trachomatis serovar
D and then fixed and stained with antibodies to ceramide (red) and
IncA (green) to identify the inclusion membrane. (B–C) HeLa cells
transfected with (B) Arf1-GFP or (C) CERT-GFP were infected
with C. trachomatis L2, and then fixed and stained with antibodies
to ceramide (red). Enlargements of the boxed regions (inset) are
shown to the right. Images represent a single z slice from confocal
images. Ceramide was localized to both the inclusion membrane
as well as the region adjacent to the inclusion. *, inclusion. Scale
bar, ,5 mm.
(TIF)
Figure S6 ER Localization in C. trachomatis-infected
cells expressing CERT domain mutants. HeLa cells were
transfected with CERT-GFP, CERT (D324A)-GFP, or CERT
(G67E)-GFP, infected with C. trachomatis L2 for 24 hrs, and then
fixed and stained with antibodies to calnexin (red) to identify the
ER. The exposure time for each filter set of all images was
identical. Images shown are maximum intensity projections of
confocal z-stacks (0.4-mm slices). The ER does not colocalize with
wild type or mutant CERT at the inclusion. N, host nucleus;
*, inclusion. Scale bar=5 mm.
(TIF)
Figure S7 Palmitoylation is not required for SMS2
recruitment to the inclusion. HeLa cells transfected for
18 hrs with C-terminally 3xFLAG-tagged SMS1, 3xFLAG-tagged
SMS2, or 3xFLAG-tagged SMS2 palmitoylation mutant (C331,
332, 343, 348A) were infected with C. trachomatis L2 for 24 hrs and
then fixed and stained with anti-FLAG (red). Bacteria and host
DNA were detected using DAPI (blue). The SMS2 palmitoylation
mutant was recruited to the inclusion membrane. N, host nucleus;
*, inclusion. Scale bar=5 mm.
(TIF)
Video S1 CERT-GFP distribution on C. trachomatis
inclusions. HeLa cells transfected for 18 hrs with CERT-GFP
were infected with C. trachomatis L2 for 24 hrs. Confocal z-slices
were taken every 0.4 mm and processed using IMARIS software to
obtain a three dimensional (3D) reconstruction of the area.
CERT-GFP decorates the inclusion membrane surface in a non-
homogenous, patchy distribution.
(MOV)
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